AgomAb Therapeutics (NASDAQ:AGMB) Stock: Insider David Epstein Acquires 5,000 Shares

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 5,000 shares of AgomAb Therapeutics stock in a transaction that occurred on Tuesday, October 6th. The shares were purchased at an average cost of $8.70 per share, with a total value of $43,500.00. Following the completion of the acquisition, the director owned 10,000 shares of the company’s stock, valued at $87,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AgomAb Therapeutics Price Performance

AgomAb Therapeutics stock opened at $9.22 on Friday. AgomAb Therapeutics NV has a fifty-two week low of $7.97 and a fifty-two week high of $17.82. The stock’s fifty day moving average is $12.68 and its two-hundred day moving average is $11.95.

AgomAb Therapeutics (NASDAQ:AGMB) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Research analysts anticipate that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

AgomAb Therapeutics News Summary

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: CEO Tim Jasper Knotnerus purchased 11,000 shares across October 5–6 for approximately $94,380, increasing his ownership substantially. CFO Pierre Kemula also bought 10,000 shares for about $85,900, while director David Epstein acquired 5,000 shares for $43,500. The coordinated insider buying may be viewed as a signal of management and board confidence in AgomAb’s long-term prospects. Insider Buying: AgomAb Therapeutics CEO Purchases Shares
• Positive Sentiment: AgomAb plans to present STENOVA open-label extension data for ontunisertib at UEG Week 2026 and host a scientific symposium focused on fibro-inflammation. The event could provide investors with additional information on the drug’s durability, safety and potential in inflammatory diseases. AgomAb UEG Week 2026 Presentation
• Neutral Sentiment: The planned presentation is a potential near-term catalyst, but the announcement did not include the actual clinical results. Investors will likely await the data before reassessing the program’s prospects.
• Negative Sentiment: AgomAb remains a clinical-stage biotechnology company reporting quarterly losses, with analysts expecting a full-year loss of approximately $1.76 per share. Shares are also trading below their 50-day and 200-day moving averages, reflecting continued volatility and execution risk.

Wall Street Analyst Weigh In

Several analysts have issued reports on AGMB shares. B. Riley Financial began coverage on shares of AgomAb Therapeutics in a report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target on the stock. HC Wainwright restated a “buy” rating on shares of AgomAb Therapeutics in a research report on Wednesday, September 16th. Piper Sandler started coverage on AgomAb Therapeutics in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 target price on the stock. Cantor Fitzgerald began coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating on the stock. Finally, Wall Street Zen downgraded AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, September 27th. Seven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.